Crinetics Pharmaceuticals Inc
NASDAQ:CRNX
Crinetics Pharmaceuticals Inc
NASDAQ:CRNX
Price:
46.86 USD
-1.29%
Market Closed
Updated:
May 29, 2024
Crinetics Pharmaceuticals Inc
Operating Income
|
Crinetics Pharmaceuticals Inc
Operating Income Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Crinetics Pharmaceuticals Inc
NASDAQ:CRNX
|
Operating Income
-$248.2m
|
CAGR 3-Years
-46%
|
CAGR 5-Years
-50%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Operating Income
$16B
|
CAGR 3-Years
6%
|
CAGR 5-Years
6%
|
CAGR 10-Years
11%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Operating Income
$8.7B
|
CAGR 3-Years
24%
|
CAGR 5-Years
1%
|
CAGR 10-Years
3%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Operating Income
$7.1B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
2%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Operating Income
$4.2B
|
CAGR 3-Years
12%
|
CAGR 5-Years
39%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Operating Income
$4B
|
CAGR 3-Years
0%
|
CAGR 5-Years
10%
|
CAGR 10-Years
17%
|
See Also
What is Crinetics Pharmaceuticals Inc's Operating Income?
Operating Income
-248.2m
USD
-248.2m
USD
Based on the financial report for Mar 31, 2024, Crinetics Pharmaceuticals Inc's Operating Income amounts to -248.2m USD.
What is Crinetics Pharmaceuticals Inc's Operating Income growth rate?
Operating Income CAGR 5Y
-50%
-50%
Over the last year, the Operating Income growth was -36%. The average annual Operating Income growth rates for Crinetics Pharmaceuticals Inc have been -46% over the past three years , -50% over the past five years .
You don't have any saved screeners yet
